1 completed, 1 unknown, 1 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Dfmo: new trials by email Literature Review of Dfmo trials Research Report on Dfmo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Eflornithine, Lomustine - Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma | Phase 3 | Unknown | Orbus Therapeutics, Inc. | 343 | 2016-07-01 | 2022-01-21 |
| A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis | Phase 3 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2011-03-01 | 2015-04-24 | |
| Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps placebo, eflornithine, sulindac - Precancerous Condition | Phase 3 | Completed | National Cancer Institute (NCI) | 375 | 1998-07-01 | 2015-01-22 |
Adenomatous Polyposis Coli (1) · Astrocytoma (1) · Brain Neoplasms (1) · Colonic Polyps (1) · Glioma (1) · Precancerous Conditions (1)
Cancer Prevention Pharmaceuticals, Inc. (1) · National Cancer Institute (NCI) (1) · Orbus Therapeutics, Inc. (1)
United States (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Alfred M. Cohen, M.D. (1) · Frank Meyskens (1)
R01CA088078 (1)